Anteris Technologies (ASX:AVR) has enrolled and successfully treated the first US patients in its PARADIGM global pivotal trial of the DurAVR transcatheter heart valve for severe calcific aortic stenosis, according to a Wednesday Australian bourse filing.
The procedures were carried out at Montefiore Medical Center in New York, the filing added.
The company's shares rose 6% in recent Wednesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.